Vivos Therapeutics, Inc. (NASDAQ: VVOS) reported Q3 EPS of ($0.26), $0.01 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $3.72 million.

For earnings history and earnings-related data on Vivos Therapeutics, Inc. (VVOS) click here.